Chronic heart failure and hypoalbuminaemia are linked to a poor antibody response at 3 months after the third dose of the ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

More information: An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses, Science Immunology (2025). DOI: 10.1126/sciimmunol.ads1328 ...

IMUNON announces promising Phase 1 results for IMNN-101, a DNA plasmid vaccine demonstrating enhanced durability and potential advantages over mRNA vaccines. Quiver AI Summary IMUNON, Inc., a ...

A medical panel appointed by US Health Secretary Robert F. Kennedy Jr. held its first meeting Wednesday, pledging to revisit ...

Trump and Musk reignite feud over tax bill, stocks end first half at records, Moderna flu vaccine achieves promising results, ...

We came across a bullish thesis on Moderna, Inc. (MRNA) on Natan’s Substack. In this article, we will summarize the bulls’ ...

The paper also " paves the way to explore rationally designed mRNA vaccine adjuvants moving forward, capitalizing on decades of cytokine biology research," Aunins says.

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the most active stocks to buy according to analysts. On June 13, Ethris ...